EVA Select服務

替身醫療(Avatar medicine)是透過搜集患者的檢體或數據,建立出「替身」代替患者嘗試不同的治療,讓患者無需再以身試藥。癌症治療也從傳統的「對症下藥」演進至「個人化用藥」的時代。

最新消息

CancerFree Biotech won the top honor, the KOZAROCKS AWARD, at the KOZAROCKS 2024 event in Okinawa, recognizing their personalized tumor cell analysis technology. Turing Drive, another Taiwanese team, received the GxPartners AWARD for their innovative autonomous driving solutions. The event, which fosters startup collaboration and innovation, highlighted the growing influence of Taiwanese startups on the international stage.
CancerFree Biotech, a Taiwanese startup, was selected to participate in OIST's prestigious startup accelerator program in Okinawa, Japan. The company's innovative "Avatar Medicine" technology, which simulates tumor responses to various drugs, has gained international recognition for its potential to improve cancer treatment. With access to OIST’s world-class research facilities and mentorship, CancerFree Biotech aims to accelerate its technology’s entry into the Japanese market and further explore personalized cancer treatment.
CancerFree Biotech won two prestigious awards at the Asian Entrepreneurship Award (AEA) in Japan, marking the fourth time the company has received an international award in 2025. The company’s "Avatar Medicine," which helps cancer patients with drug testing using tumor organoids, gained significant international recognition. This year’s event, held in Kashiwa-no-ha, Chiba, was the first in-person AEA in five years and highlighted the growing importance of innovation ecosystems in Asia.
CancerFree Biotech has received two special awards from the Tokyo Government and Shimizu Construction, becoming the only Taiwanese company in the top 20 of the "SusHi Tech Tokyo Global Startup Program 2024". Its cancer stand-in medical technology drives personalized treatment, creates new opportunities for cancer patients, and showcases Taiwan's excellence in innovation in the field of biotechnology.

分類

標籤

我們期望成為癌症患者的守護者、成為醫療人員的夥伴。

我們的目標,是降低治療過程中癌症病患的痛苦與風險,提升黃金治療時間內的用藥精準。

​LINE 聯絡我們